PT Staff

Products include multivitamin gummies and a superfood supplement.

FDA action allows for OTC naloxone (Narcan) to be sold directly to consumers in pharmacies, convenience stores, grocery stores, gas stations, and online.

Products include a new NSAID and an oral solution for depression.

Evinacumab-dgnb (Evkeeza; Regeneron Pharmaceuticals, Inc) is the first FDA-approved treatment indicated for children as young as 5 years of age to treat dangerously high levels of LDL-C.

Although antibiotics are an effective treatment option, evidence indicates that fecal microbiota transplant holds promise in treating refractory or recurrent C difficile infections.

Indication for abemaciclib (Verzenio; Eli Lilly and Company) in combination with endocrine therapy expanded for the adjuvant treatment of adults with hormone receptor–positive, human epidermal growth factor receptor 2-negative, node-positive, early breast cancer with a high risk of recurrence.

The immunological efficacy of the 13-valent conjugate pneumococcal vaccine followed by 23-valent polysaccharide vaccine has been poorly documented in adult patients with sickle cell disease.

The inaugural Oncology Pharmacists Connect is directed toward pharmacists practicing in oncology in multiple practice environments.

Sarilumab is a fully human monoclonal antibody indicated for patients with polymyalgia rheumatica who had an inadequate response to corticosteroids or are unable to tolerate corticosteroid taper.

Products include acne patches and immune boosting power.

Altuviiio [antihemophilic factor (recombinant), Fc-VWF-XTEN fusion protein-ehtl; Sanofi] is high-sustained factor VIII replacement therapy indicated for routine prophylaxis and on-demand treatment to control bleeding episodes and for perioperative management in adults and children with hemophilia A.

Extended infusion piperacillin/tazobactam was associated with lower odds of 14-day mortality compared to standard infusion piperacillin/tazobactam.

Elranatamab is an investigational B-cell maturation antigen CD3-targeted bispecific antibody that may become the next standard of care for multiple myeloma, according to researchers.

Products range from Parkinson disease treatment to medication for epilepsy.

Products include medications for depressive disorder and migraines.

The FDA approved darolutamide in 2019 for the treatment of patients with nonmetastatic castration-resistant prostate cancer based improved metastasis-free survival.

Austedo XR will be available in 3 extended-release tablet strengths, which provides an updated regimen that may result in a lower pill count for patients.

Expanded indication for abrocitinib (Cibinqo; Pfizer Inc) includes patients 12 to <18 years of age with refractory, moderate-to-severe atopic dermatitis that is not adequately controlled with other systemic medications.

Aflibercept injection is also indicted for the treatment of neovascular age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema, and diabetic retinopathy.

Single nasal swab test can determine whether a patient has COVID-19, influenza, respiratory syncytial virus, or a combination of these viruses in as little as 2 hours.

Sacituzumab govitecan-hziy (Trodelvy) is a conjugated Trop-2-directed antibody and topoisomerase inhibitor previously approved for patients with triple-negative breast cancer.

Daprodustat (Jesduvroq, GSK) is the first oral hypoxia-inducible factor prolyl hydroxylase inhibitor to gain approval in the United States.

Amjevita is approved for all indications of reference Humira except for hidradenitis suppurativa.

Pembrolizumab approved as adjuvant treatment following surgical resection and platinum-based chemotherapy for patients with stage IB, II, or IIIA non-small cell lung cancer.

Products include drugs for patients with stroke, bacterial infections, and acute pain.

An organ transplant is a known risk factor for C. difficile infection, however, data are lacking on how the infection affects those who underwent an intestinal transplant.

Zilucoplan is among highlighted products of the month.

Bruton’s tyrosine kinase inhibitor zanubrutinib (Brukinsa; BeiGene USA, Inc) approved for the treatment of chronic lymphocytic leukemia or small lymphocytic lymphoma.

Deucravacitinib is an oral, selective, allosteric tyrosine kinase 2 inhibitor that inhibits cytokine signaling in psoriasis pathogenesis.

Research shows that some unsuccessful switches from reference products to biosimilars may be attributed to patient perceptions of reduced efficacy and safety.